Shan Zeng
Central South University(CN)Solid State Physics Laboratory(IN)Sun Yat-sen University(CN)Quanzhou Normal University(CN)South China Normal University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Fudan University(CN)Beijing Normal University(CN)California University of Pennsylvania(US)Wuhan University(CN)Meizhou City People's Hospital(CN)Hunan Provincial Center for Disease Control and Prevention(CN)First Affiliated Hospital of Sichuan Medical University(CN)Xinjiang Uygur Autonomous Region Disease Prevention and Control Center(CN)Shanghai University of Traditional Chinese Medicine(CN)Longhua Hospital Shanghai University of Traditional Chinese Medicine(CN)Suzhou Thermal Engineering Research Institute(CN)Eye & ENT Hospital of Fudan University(CN)People's Hospital of Xinjiang Uygur Autonomous Region(CN)The First Affiliated Hospital, Sun Yat-sen University(CN)Lafayette School Corporation(US)First Affiliated Hospital of Gannan Medical University(CN)Institute of High Energy Physics(CN)Sun Yat-sen University Cancer Center(CN)Second Xiangya Hospital of Central South University(CN)Xiangya Hospital Central South University(CN)Shenzhen Second People's Hospital(CN)State Key Laboratory of Medical Neurobiology
Publications by Year
Research Areas
Gastrointestinal Tumor Research and Treatment, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Immune Cell Function and Interaction, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial(2023)554 cited
- → Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido(2011)518 cited
- → The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations(2002)447 cited
- → From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma(2019)404 cited
- → Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial(2019)234 cited
- →